Latest News and Press Releases

New findings challenge the longstanding assumption that postmortem tissue accurately represents the living brain and creates new frontier for drug research

BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to...

BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma company focused on mitochondrial medicine and protein homeostasis, today welcomes Sheikh...

Company strengthens its late-stage trials with enhanced clinical and commercial leadership for its BPM31510 programs

BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced its...

BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM) and Topline Phase 2b clinical data expected in 1H 2026

BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development.The Company plans to seek guidance in Q3 2025 from...

BPGbio Presents Advances in Spatial Omics Technology and Targeted Protein Degradation Insights at ASMS 2025

BPGbio CEO Dr. Niven R. Narain was named to The Medicine Maker Power List 2025.

BPGbio highlights groundbreaking data on BPM31510 illustrating it's therapeutic impact as a potential treatment for primary CoQ10 deficiency.